Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel

M. Zambetti, G. Mariani, R. Demicheli, P. Verderio, P. Potepan, F. Garbagnati

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer. We investigated the combination of this two antitumor drugs with the aim to determine a tolerant and active second-line therapy in metastatic pretreated patients. Patients and methods. Fifty six patients pretreated with chemotherapy received a median of six cycles [2-11] of fluorouracil, 700 mg/m2 for 5 day-continuous i.v. infusion and vinorelbine, 20 mg/m2 on days 1 and 6, every three weeks. The inclusion and evaluation criteria required measurable disease by conventional clinical and/or instrumental means. Findings. latrogenic toxicity in 340 administered cycles was mild: stomatitis = 11% (Grade 3 = 5%), constipation and abdominal pain = 12%, G2 neutropenia = 4%, G1 thrombocytopenia = 0.5%. In nine cases moderate infections occurred and six women experienced catheter related complications. Complete and partial remissions were observed in 12% and 36% of evaluable patients, respectively. In particular major tumor regression was documented in 28% of anthracyclines or taxol unresponsive cases. Conclusions. This drug combination is active in metastatic pretreated breast cancer patients and devoid of serious iatrogenic toxicity. Although it deserves future optimization, for instance with the inclusion of oral fluoropirimidines, it represents a good choice for second-line or non cross-resistant regimens.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalBreast Cancer Research and Treatment
Volume62
Issue number2
DOIs
Publication statusPublished - 2000

Fingerprint

Anthracyclines
Paclitaxel
Fluorouracil
Breast Neoplasms
Stomatitis
Drug Combinations
Constipation
Neutropenia
Antineoplastic Agents
Abdominal Pain
Catheters
vinorelbine
Pharmacology
Drug Therapy
Infection
Pharmaceutical Preparations
Neoplasms

Keywords

  • Metastatic breast cancer
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. / Zambetti, M.; Mariani, G.; Demicheli, R.; Verderio, P.; Potepan, P.; Garbagnati, F.

In: Breast Cancer Research and Treatment, Vol. 62, No. 2, 2000, p. 135-139.

Research output: Contribution to journalArticle

@article{d21a4fabd49346378379950e1439fa72,
title = "Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel",
abstract = "The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer. We investigated the combination of this two antitumor drugs with the aim to determine a tolerant and active second-line therapy in metastatic pretreated patients. Patients and methods. Fifty six patients pretreated with chemotherapy received a median of six cycles [2-11] of fluorouracil, 700 mg/m2 for 5 day-continuous i.v. infusion and vinorelbine, 20 mg/m2 on days 1 and 6, every three weeks. The inclusion and evaluation criteria required measurable disease by conventional clinical and/or instrumental means. Findings. latrogenic toxicity in 340 administered cycles was mild: stomatitis = 11{\%} (Grade 3 = 5{\%}), constipation and abdominal pain = 12{\%}, G2 neutropenia = 4{\%}, G1 thrombocytopenia = 0.5{\%}. In nine cases moderate infections occurred and six women experienced catheter related complications. Complete and partial remissions were observed in 12{\%} and 36{\%} of evaluable patients, respectively. In particular major tumor regression was documented in 28{\%} of anthracyclines or taxol unresponsive cases. Conclusions. This drug combination is active in metastatic pretreated breast cancer patients and devoid of serious iatrogenic toxicity. Although it deserves future optimization, for instance with the inclusion of oral fluoropirimidines, it represents a good choice for second-line or non cross-resistant regimens.",
keywords = "Metastatic breast cancer, Second-line chemotherapy",
author = "M. Zambetti and G. Mariani and R. Demicheli and P. Verderio and P. Potepan and F. Garbagnati",
year = "2000",
doi = "10.1023/A:1006445713773",
language = "English",
volume = "62",
pages = "135--139",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel

AU - Zambetti, M.

AU - Mariani, G.

AU - Demicheli, R.

AU - Verderio, P.

AU - Potepan, P.

AU - Garbagnati, F.

PY - 2000

Y1 - 2000

N2 - The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer. We investigated the combination of this two antitumor drugs with the aim to determine a tolerant and active second-line therapy in metastatic pretreated patients. Patients and methods. Fifty six patients pretreated with chemotherapy received a median of six cycles [2-11] of fluorouracil, 700 mg/m2 for 5 day-continuous i.v. infusion and vinorelbine, 20 mg/m2 on days 1 and 6, every three weeks. The inclusion and evaluation criteria required measurable disease by conventional clinical and/or instrumental means. Findings. latrogenic toxicity in 340 administered cycles was mild: stomatitis = 11% (Grade 3 = 5%), constipation and abdominal pain = 12%, G2 neutropenia = 4%, G1 thrombocytopenia = 0.5%. In nine cases moderate infections occurred and six women experienced catheter related complications. Complete and partial remissions were observed in 12% and 36% of evaluable patients, respectively. In particular major tumor regression was documented in 28% of anthracyclines or taxol unresponsive cases. Conclusions. This drug combination is active in metastatic pretreated breast cancer patients and devoid of serious iatrogenic toxicity. Although it deserves future optimization, for instance with the inclusion of oral fluoropirimidines, it represents a good choice for second-line or non cross-resistant regimens.

AB - The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer. We investigated the combination of this two antitumor drugs with the aim to determine a tolerant and active second-line therapy in metastatic pretreated patients. Patients and methods. Fifty six patients pretreated with chemotherapy received a median of six cycles [2-11] of fluorouracil, 700 mg/m2 for 5 day-continuous i.v. infusion and vinorelbine, 20 mg/m2 on days 1 and 6, every three weeks. The inclusion and evaluation criteria required measurable disease by conventional clinical and/or instrumental means. Findings. latrogenic toxicity in 340 administered cycles was mild: stomatitis = 11% (Grade 3 = 5%), constipation and abdominal pain = 12%, G2 neutropenia = 4%, G1 thrombocytopenia = 0.5%. In nine cases moderate infections occurred and six women experienced catheter related complications. Complete and partial remissions were observed in 12% and 36% of evaluable patients, respectively. In particular major tumor regression was documented in 28% of anthracyclines or taxol unresponsive cases. Conclusions. This drug combination is active in metastatic pretreated breast cancer patients and devoid of serious iatrogenic toxicity. Although it deserves future optimization, for instance with the inclusion of oral fluoropirimidines, it represents a good choice for second-line or non cross-resistant regimens.

KW - Metastatic breast cancer

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033821811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033821811&partnerID=8YFLogxK

U2 - 10.1023/A:1006445713773

DO - 10.1023/A:1006445713773

M3 - Article

C2 - 11016751

AN - SCOPUS:0033821811

VL - 62

SP - 135

EP - 139

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -